Plain-English translation of NCT06062966 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Heart Failure research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a medication called , which blocks a key inflammatory chemical in the body called IL-1. Researchers believe that in patients with advanced heart failure who are already taking inotrope drugs (medicines that help the heart pump harder), reducing this inflammation may help their hearts respond better to those medications and work more effectively.
People with very advanced heart failure often need intravenous drugs called inotropes to help their hearts pump blood, but these drugs can become less effective over time and carry serious risks. This medication may reduce inflammation that interferes with how well inotropes work, potentially allowing doctors to use lower, safer doses while still helping patients feel better.
You likely qualify if…
You likely don't qualify if…
You would receive the medication (given by injection) and follow a study protocol that likely includes blood work, heart function tests, and possibly an exercise test to see how your heart responds. The study is small (20 participants) and is in its early testing phase, so visits and duration would be determined by the research team at Virginia Commonwealth University. You would need to be able to follow instructions carefully and attend all scheduled appointments.
AI-generated summary from trial data · Jul 17, 2026 · Not medical advice
United States